143 related articles for article (PubMed ID: 26602960)
1. The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Song Q; Zhou X; Yu J; Dong N; Wang X; Yang H; Ren J; Lyerly HK
Sci Rep; 2015 Nov; 5():16775. PubMed ID: 26602960
[TBL] [Abstract][Full Text] [Related]
2. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
Zhou X; Qiao G; Wang X; Song Q; Morse MA; Hobeika A; Gwin WR; Ren J; Lyerly HK
Cancer Chemother Pharmacol; 2018 Feb; 81(2):365-372. PubMed ID: 29242966
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract][Full Text] [Related]
7. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.
Ren J; Di L; Song G; Yu J; Jia J; Zhu Y; Yan Y; Jiang H; Liang X; Che L; Zhang J; Wan F; Wang X; Zhou X; Lyerly HK
Clin Transl Oncol; 2013 Oct; 15(10):780-8. PubMed ID: 23359185
[TBL] [Abstract][Full Text] [Related]
8. [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Yu J; DI Lj; Song Gh; Che L; Jiang Hf; Zhu Yl; Liang X; Jia J; Zhang J; Yang Hb; Wang Xl; Zhou Xn; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):151-6. PubMed ID: 21321641
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Heery CR; Ibrahim NK; Arlen PM; Mohebtash M; Murray JL; Koenig K; Madan RA; McMahon S; Marté JL; Steinberg SM; Donahue RN; Grenga I; Jochems C; Farsaci B; Folio LR; Schlom J; Gulley JL
JAMA Oncol; 2015 Nov; 1(8):1087-95. PubMed ID: 26291768
[TBL] [Abstract][Full Text] [Related]
10. Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics.
Kassogue Y; Diakite B; Kassogue O; Konate I; Tamboura K; Diarra Z; Maiga M; Dehbi H; Nadifi S; Traore CB; Kamate B; Dao S; Doumbia S; Dolo G
Medicine (Baltimore); 2021 Jul; 100(29):e26614. PubMed ID: 34398016
[TBL] [Abstract][Full Text] [Related]
11. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
12. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
13. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
15. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
Lévy P; Gligorov J; Antoine M; Rezai K; Lévy E; Selle F; Saintigny P; Lokiec F; Avenin D; Beerblock K; Lotz JP; Bernaudin JF; Fajac A
Breast Cancer Res Treat; 2013 Jun; 139(2):421-8. PubMed ID: 23666532
[TBL] [Abstract][Full Text] [Related]
16. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
Chen L; Qi H; Zhang L; Li H; Shao J; Chen H; Zhong M; Shi X; Ye T; Li Q
BMC Cancer; 2018 Oct; 18(1):1038. PubMed ID: 30359238
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.
Andre F; Broglio K; Pusztai L; Berrada N; Mackey JR; Nabholtz JM; Chan S; Hortobagyi GN
Oncologist; 2010; 15(5):476-83. PubMed ID: 20421265
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M
Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859
[TBL] [Abstract][Full Text] [Related]
19. Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
Korantzis I; Kalogeras KT; Papaxoinis G; Kotoula V; Koutras A; Soupos N; Papakostas P; Dionysopoulos D; Samantas E; Christodoulou C; Linardou H; Pectasides D; Fountzilas G
Anticancer Res; 2012 Oct; 32(10):4569-80. PubMed ID: 23060588
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Kim HJ; Im SA; Keam B; Ham HS; Lee KH; Kim TY; Kim YJ; Oh DY; Kim JH; Han W; Jang IJ; Kim TY; Park IA; Noh DY
Cancer Sci; 2015 Jan; 106(1):86-93. PubMed ID: 25410489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
